Zenith Epigenetics   Report issue

For profit Phase 1 Phase 2
Founded: Calgary Canada (2013)

Organization Overview

First Clinical Trial
2014
NCT02238522
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Zenith Epigenetics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Small Cell (Phase 2)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 7